TTLL4

TTLL4 is a branch-initiating (initiase) protein glutamylase that catalyzes the addition of a single glutamate via an isopeptide bond to internal glutamate residues on diverse substrates, without elongating the resulting branch (PMID:32747782, PMID:41770829). Its substrate range extends well beyond tubulin: it is the predominant cellular polyglutamylase in HeLa cells and recognizes glutamate-rich stretches in target proteins, modifying the nucleosome assembly proteins NAP1/NAP2 in vitro (PMID:18045879). On microtubules, TTLL4 acts preferentially on α-tubulin isoforms in brain and deposits initiator sites that constrain downstream elongation by TTLL7, with distinct effects on kinesin motility (PMID:37321451). Through monoglutamylation of non-tubulin substrates, TTLL4 controls multiple cellular programs: it monoglutamylates the DNA sensor cGAS to block its cGAMP-synthase activity and suppress antiviral signaling (PMID:26829768); it modifies the histone chaperones Nap1 and Npm2 within acidic disordered regions to enhance their DNA electrostatic mimicry and promote nucleosome assembly (PMID:38571760); it glutamylates IL-7Rα to trigger STAT5/Sall3 signaling and ILC3 differentiation (PMID:28794449); and it glutamylates Klf4 at Glu381 to block Lys48-linked ubiquitination, stabilizing Klf4 and enabling reprogramming and early embryogenesis (PMID:29593216). In red blood cells its sole target is NAP1, whose glutamylation drives membrane association and cytoskeletal organization (PMID:27974641). TTLL4 activity is negatively regulated by NEK5 kinase, which binds TTLL4 and phosphorylates it at Y815 and S1136 to dampen polyglutamylation (PMID:34084286). Genetic loss of TTLL4 suppresses ciliary degeneration in C. elegans deglutamylase mutants and attenuates Purkinje cell, mitral cell, and photoreceptor degeneration in pcd mice, identifying TTLL4 as a source of pathological hyperglutamylation (PMID:21982591, PMID:33064774, PMID:35404950).

1. 2007 High

   Established that TTLL4 is an enzymatically active polyglutamylase with a broad non-tubulin substrate range, answering whether the TTLL family member acted only on tubulin.

   Evidence In vitro polyglutamylation assay with recombinant TTLL4 plus proteomic substrate identification and HeLa knockdown/overexpression

   PMID:18045879

   Open questions at the time

   • Did not define the chemistry of the modification (initiation vs elongation)
   • Physiological relevance of NAP1/NAP2 modification not established in vivo
2. 2010 Medium

   Genetic loss-of-function placed the TTLL4 ortholog as a glutamylase of axonemal microtubules in sensory cilia and identified PELP1 as a chromatin-linked substrate, extending substrate scope to cilia and transcriptional machinery.

   Evidence C. elegans ttll-4 mutants with anti-glutamylation immunostaining; shRNA knockdown and Co-IP of PELP1 in pancreatic cancer cells

   PMID:20442285 PMID:20519502

   Open questions at the time

   • Direct enzyme-substrate catalysis on PELP1 not reconstituted in vitro
   • Functional consequence of ciliary glutamylation not yet defined
3. 2011 High

   Genetic epistasis defined TTLL4 as the glutamylase upstream of CCP-mediated deglutamylation, showing its activity is the source of damaging hyperglutamylation on ciliary microtubules.

   Evidence ttll-4; ccpp-1 double mutant analysis with ciliary dye-filling and immunostaining in C. elegans

   PMID:21982591 PMID:33064774

   Open questions at the time

   • Mammalian equivalent of the ciliary degeneration axis not directly tested here
   • Glutamate chain length on damaging sites not quantified
4. 2016 High

   Identified two distinct physiological substrate axes — cGAS for innate immune control and NAP1 for erythrocyte cytoskeleton — demonstrating TTLL4 monoglutamylation as a tunable regulatory switch with dedicated erasers.

   Evidence Overexpression/knockdown with cGAMP and glutamylation assays plus CCP5 rescue; Ttll4 KO mice with GT335 IP, ultrastructure, and hemolysis assays

   PMID:26829768 PMID:27974641

   Open questions at the time

   • Structural basis for substrate selection across cGAS vs NAP1 unknown
   • How upstream signals direct TTLL4 to specific substrates not defined
5. 2017 High

   Linked TTLL4 glutamylation of IL-7Rα to STAT5/Sall3 signaling and ILC3 differentiation, establishing a receptor-modifying role in immune cell fate.

   Evidence Ttll4 KO mice, IL-7Rα glutamylation measurement, STAT5 assays, and IL-7Rα E446A knockin

   PMID:28794449

   Open questions at the time

   • Mechanism by which receptor glutamylation potentiates STAT5 activation not resolved
   • Relative contributions of TTLL4 vs TTLL13 to the modification unclear
6. 2018 High

   Revealed glutamylation-ubiquitination crosstalk: TTLL4 modification of Klf4 at Glu381 blocks K48 ubiquitination and stabilizes the factor, connecting the enzyme to reprogramming and embryogenesis; concurrently showed p38 MAPK activates the ciliary ortholog.

   Evidence Klf4-E381A knockin mice, KO/knockdown, ubiquitination and iPSC assays; phosphosite mutagenesis with IFT velocity readout in C. elegans

   PMID:29593216 PMID:29849065

   Open questions at the time

   • Whether ubiquitination blocking generalizes to other substrates unknown
   • Direct kinase-to-TTLL4 phosphorylation in mammals not mapped here
7. 2020 High

   Structural and engineering work defined TTLL4 mechanistically as a pure branch-initiase that adds the first isopeptide-linked glutamate but cannot elongate, while overexpression studies tied it to vesicle/exosome biogenesis in cancer.

   Evidence Co-crystal structures with tetrahedral intermediate analogs and initiase/elongase active-site mutagenesis; TTLL4 overexpression with live imaging, NTA, TEM, and BBB permeability assays

   PMID:32747782 PMID:32998758

   Open questions at the time

   • Initiase chemistry shown via TTLL6 surrogate structures, not TTLL4 crystal directly
   • Causal link between tubulin glutamylation and exosome cargo selection partially inferred
8. 2021 Medium

   Defined NEK5 as a direct binding partner and negative regulator of TTLL4 via phosphorylation at Y815 and S1136, establishing post-translational control of glutamylase output.

   Evidence Yeast two-hybrid, reciprocal Co-IP, MS phosphosite mapping, point mutagenesis, and NEK5 siRNA with glutamylation readout

   PMID:34084286

   Open questions at the time

   • Single lab; structural basis of inhibition unknown
   • Physiological contexts where NEK5 controls TTLL4 not defined
9. 2022 High

   Genetic rescue in pcd mice established TTLL4 as a clinically relevant driver of neurodegenerative hyperglutamylation, with a substrate/site profile distinct from TTLL1.

   Evidence Ttll4 KO crossed into pcd mice with histology of Purkinje, mitral, and photoreceptor cells and rhodopsin trafficking assays

   PMID:35404950

   Open questions at the time

   • Specific tubulin sites responsible for neuronal toxicity not pinpointed
   • Only partial rescue of photoreceptor phenotype
10. 2023 High

    Resolved how TTLL4 cooperates with elongases on neuronal microtubules — preferentially initiating on α-tubulin and constraining TTLL7 elongation — with consequences for kinesin behavior.

    Evidence In vitro glutamylation with purified recombinant TTLL4, tandem MS site mapping, and kinesin motility assays

    PMID:37321451

    Open questions at the time

    • In vivo significance of the TTLL4/TTLL7 division of labor not tested
    • Effect on other microtubule motors beyond kinesin unknown
11. 2025 Medium

    Extended the Klf4 stabilization paradigm to oncogenic NPM1c: TTLL4 monoglutamylation at E126 maintains cytoplasmic NPM1c and a differentiation block, nominating TTLL4 as an AML target druggable by EN7.

    Evidence Multiple genetic TTLL4 inactivation approaches in NPM1c cell lines, Ttll4 KO NPM1c/NRAS mouse AML model, transcriptomics, and EN7 inhibitor (preprint)

    PMID:bio_10.1101_2025.04.07.647605

    Open questions at the time

    • Preprint, not yet peer-reviewed
    • EN7 selectivity and off-target profile not fully established
    • Mechanism by which E126 glutamylation enforces cytoplasmic retention not resolved
12. 2026 Medium

    Confirmed in human cells that TTLL4 is a chain-initiator whose overexpression raises glutamylation without disrupting microtubule dynamics, and is pharmacologically blockable by LDC10.

    Evidence TTLL4 overexpression in HEK293T with EB3 live imaging, glutamylation immunofluorescence, and LDC10 inhibitor treatment

    PMID:41770829

    Open questions at the time

    • Single lab; endogenous TTLL4 not tested
    • Inhibitor specificity across the TTLL family not characterized

• How TTLL4 selects among its many substrates (tubulin, cGAS, Klf4, NPM1c, IL-7Rα, NAP1, Npm2) in a given cellular context, and how upstream signaling reroutes this selectivity, remains unresolved.
• No structural model of TTLL4 bound to a non-tubulin substrate
• Determinants of substrate choice beyond glutamate-rich stretches unknown
• Cell-type-specific regulation of substrate repertoire undefined